Treatment of HCV infection with interferon alpha-2b and ribavirin in a patient with X-linked lymphoproliferative syndrome.
Chronic hepatitis C (HCV) infection in patients with primary immunodeficiency increases the risk of an accelerated progression of HCV-related liver disease. Here, we report a patient with X-linked lymphoproliferative syndrome infected with HCV and Epstein-Barr virus (EBV). After combination treatment with interferon alpha-2b and ribavirin, clearance of HCV-RNA was achieved, and noteworthily, EBV DNA also became undetectable.
Strnad-Trojan
Nicola
N
Department of Paediatrics, Johann Wolfgang Goethe University Medical Centre, Frankfurt am Main, Germany. trojan@em.uni-frankfurt.de
Linde
Richard
R
Reichenbach
Janine
J
Trojan
Jörg
J
Zeuzem
Stefan
S
Zielen
Stefan
S
D000998:Antiviral Agents / Q000627:therapeutic use*; D002648:Child; D004279:DNA, Viral / Q000032:analysis; D004359:Drug Therapy, Combination; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000188:drug therapy; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008232:Lymphoproliferative Disorders / Q000150:complications*; D012367:RNA, Viral / Q000032:analysis; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*
D000998:Antiviral Agents; D004279:DNA, Viral; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D012254:Ribavirin